Excellent Earnings Propelled Prices of These 10 Firms

7. BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Shares of BridgeBio rallied by 5.33 percent on Wednesday to finish at $38.36 each as investors cheered the company’s sales from its new heart drug, beating analyst expectations.

In its latest earnings release, BridgeBio Pharma, Inc. (NASDAQ:BBIO) said that its heart treatment Attruby was gaining traction with 2,072 prescriptions written by 756 prescribers as of April 25. The momentum built on encouraging numbers released in February helped propel the company’s share price.

Attruby’s positive development offset the company’s dismal earnings performance during the first quarter of the year.

During the period, BridgeBio Pharma, Inc. (NASDAQ:BBIO) widened its net loss by 371 percent to $169.6 million from $36 million in the same period a year earlier, while revenues fell by 45 percent to $116 million from $211 million year-on-year.  Of the total revenue, $36.7 million was attributed to Attruby.